How to do robotic lateral pelvic lymph node dissection for low rectal cancer using Da <scp>Vinci‐Xi</scp> system

Cheong, Ju Yong; Shin, Seon Hui; Kim, Jin; Kim, Seon Hahn

doi:10.1111/ans.17251

Cited by 1 publication

(1 citation statement)

References 8 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to a global cancer statistics report published by Ca in February 2021, colorectal cancer mortality and morbidity rank second and third among all cancers, respectively, and have an increasing trend year by year. In China, rectal cancer mostly occurs in middle and low rectal cancer, and a large number of anatomical evidence has confirmed the presence of lateral lymph node metastasis (LLNM) in middle and low rectal cancer [1]. According to two Japanese multicenter studies, the incidence of LLNM in low rectal cancer is about 13.3% to 20.1%, and LLNM is indeed one of the main causes of local recurrence in advanced low rectal cancer.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Radical Resection of Rectal Cancer Combined with Selective Lateral Lymph Node Dissection in the Treatment of Low Rectal Cancer under Meta-analysis

Hou

Chen

et al. 2022

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

Rectal cancer mostly occurs in the middle and low position in China, and many anatomical evidence has confirmed that Lateral Lymph Node Metastasis (LLNM) exists in middle and low rectal cancer. Laparoscopic surgery can penetrate into the pelvic cavity and magnify and narrow the visual field, which is helpful for lymph node dissection and vascular nerve protection, while it has minimally invasive characteristics and is considered to be more suitable for LLND. Relevant articles published from January 2000 to May 2022 are searched using “Rectal cancer, Lateral lymph node dissection, Radical resection of rectal cancer, Low rectal cancer, Laparoscopic therapy, Treatment of rectal cancer” as test terms, analyzed and assessed using Rev Man 5.3 software and Stata software to assess the risk bias of included references, and heterogeneity among each study is evaluated using Q test and heterogeneity (I2). The experimental results show that there is no heterogeneity among the studies (I2 = 8.46%). The heterogeneity of lymphatic metastasis in the included literature is evaluated, and the results show that there is heterogeneity between the studies (I2 = 52.06%).

show abstract

Section: Introductionmentioning

confidence: 99%